GlassScriptPhysician profile
Saad Yousuf
NPI 1477814960
$695.97
in general payments reported to CMS, 2019-2025
13 companies · $85.67 in 2025
The $85.67 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.13 · 2021: $11.92 · 2022: $239 · 2023: $161 · 2024: $151 · 2025: $85.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.22 |
| Education | $152.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $162.83 | 2020-2024 | Tecvayli |
| Incyte Corporation | $99.95 | 2023 | |
| Medtronic, INC. | $76.20 | 2022 | |
| Merck Sharp & Dohme LLC | $73.88 | 2022-2024 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $60.70 | 2022-2023 | Opdivo |
| Alexion Pharmaceuticals, INC. | $50.92 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $41.78 | 2024-2025 | Enhertu |
| Abbvie INC. | $32.93 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.74 | 2025 | Austedo Xr |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Agios Pharmaceuticals, INC. | $21.38 | 2022 | |
| Pfizer INC. | $13.86 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Yousuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.